Alnylam Pharmaceuticals Stock Rating Reaffirmed by Zacks (ALNY)
Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “neutral” rating reaffirmed by Zacks in a research report issued to clients and investors on Thursday, Analyst Ratings Network reports. They currently have a $67.00 target price on the stock. Zacks‘ target price points to a potential upside of 5.21% from the company’s current price.
Zacks‘ analyst wrote, “Alnylam’s third quarter 2013 net loss of $0.48 per share was wider than the year-ago loss and the Zacks Consensus Estimate of a loss of $0.38 per share due to lower revenues. We are nonetheless encouraged by Alnylam’s progress with its pipeline, especially the ATTR program. We are also encouraged by the company’s collaborations with big pharmaceutical companies. However, the mid and early-stage nature of the company’s pipeline remains a concern. Any negative news related to the pipeline will weigh heavily on the stock. We see limited upside potential from current levels and hence maintain our Neutral stance on Alnylam.”
Separately, analysts at Leerink Swann raised their price target on shares of Alnylam Pharmaceuticals from $80.00 to $82.00 in a research note to investors on Monday, November 11th. They now have an “outperform” rating on the stock. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $64.00.
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 1.55% during mid-day trading on Thursday, hitting $64.67. The stock had a trading volume of 260,002 shares. Alnylam Pharmaceuticals has a one year low of $19.23 and a one year high of $67.97. The stock has a 50-day moving average of $61. and a 200-day moving average of $54.15. The company’s market cap is $4.102 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.09. The company had revenue of $9.00 million for the quarter, compared to the consensus estimate of $8.64 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The company’s revenue for the quarter was down 46.4% on a year-over-year basis. Analysts expect that Alnylam Pharmaceuticals will post $-1.38 EPS for the current fiscal year.
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.